Cytokinetics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Cytokinetics (CYTK) PT Lowered to $85 at Jefferies
May 23, 2024 5:59 AM EDTJefferies analyst Akash Tewari lowered the price target on Cytokinetics (NASDAQ: CYTK) to $85.00 (from $95.00) while maintaining a Buy rating.
The analyst comments "CYTK announced a $500m raise + amended its terms w/ Royalty Pharma (incl. updated royalty structure for afi, loan related to Ome... More
